Company Filing History:
Years Active: 2006-2009
Title: Ralf Landgraf: Innovator in Biomedical Research
Introduction
Ralf Landgraf is a notable inventor based in Van Nuys, California. He has made significant contributions to the field of biomedical research, particularly in the development of nucleic acid aptamers and their applications in cancer treatment.
Latest Patents
Ralf Landgraf holds 3 patents that showcase his innovative work. His latest patents include "Aptamers to human epidermal growth factor receptor-3," which provides compositions of nucleic acid aptamers that bind to the human epidermal growth factor receptor-3 and methods for their use. Another significant patent is "Methods and materials for characterizing and modulating interaction between heregulin and HER3." This patent identifies and characterizes the domain in the HER3 receptor that interacts with the heregulin ligand. It includes HER3 variant polypeptides with altered affinities for heregulin and methods for identifying compounds that bind to the heregulin binding domain in HER3.
Career Highlights
Ralf Landgraf is affiliated with the University of California, where he continues to advance his research and innovation in the biomedical field. His work has been instrumental in understanding the interactions between growth factors and their receptors, which is crucial for developing targeted therapies.
Collaborations
Ralf has collaborated with esteemed colleagues such as Elizabeth Singer and Dennis J. Slamon. These collaborations have further enriched his research and contributed to the advancement of knowledge in his field.
Conclusion
Ralf Landgraf's contributions to biomedical research through his patents and collaborations highlight his role as an innovator in the industry. His work continues to pave the way for advancements in cancer treatment and receptor biology.